Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Key Collaboration Initiated for Optimization of Bioinformatics Computing Performance

By BiotechDaily International staff writers
Posted on 03 Apr 2013
A new consortium has been formed for research and development of IT solutions to optimize computing for the analysis and management of macro-datasets generated from genomics research, as well as to facilitate clinical applications based on these datasets.

The huge sets of data produced in genomics studies, typically with Next Generation Sequencing technology, are processed by high performance computers and office workstations, and more recently by mobile devices like tablets and smartphones. The sequence of only a single human genome, for example, requires about 3 gigabytes of storage. New methods are required to process these data quickly and efficiently and to better enable their subsequent application.

Integromics (Granada, Spain) has announced that it will invest in the optimization of computing performance for bioinformatics applications, with a special focus on clinical applications, by participating in a European project named “Mr. SymBioMath” that includes renowned high performance computing (HPC) experts. The project, funded with more than EUR 2.6 million by the Seventh Framework Program for R & D of the European Union and coordinated by the Laboratory of Bioinformatics and Information Technology of the University of Malaga-UMA (Spain), has been designed to provide solutions to these needs through synergy between Integromics (Spain), the Leibniz Supercomputing Centre in Munich-LRZ (Germany), the Johannes Kepler University of Linz-JKU (Austria), RISC Software (Austria), and Carlos Haya Hospital (Spain).


The Mr. SymBioMath project is to result in new software applications and data analysis methods to accelerate genomics adoption in the clinical domain. At the level of computation, the research will be focused on two major challenges: transmission of large volumes of data and optimization of genetic comparison models and visualizations. JKU will be responsible for creating new models for comparative genomics, evolutionary distances between different organisms, and identification of correlations between genetic variation and phenotypic response of patients to particular treatments. The supercomputing infrastructure will be provided by the UMA and RISC. They will also develop applications to deliver, collect, and display test information. LRZ will focus on the provisioning of enhanced visualization and Virtual Reality hardware and software for the analysis of the interconnected huge genomic datasets in this project.

The final implementation into commercial software will be done by Integromics. “Integromics will contribute from a commercial perspective in the design of applications compatible with both computer and tablets-smartphones,” said Juan Elvira, CTO of Integromics. At the clinical level, Miguel Blanco, Chief of Allergy Carlos Haya Hospital, explained that the project will use data available in the National Allergy Network to validate the software solutions; e.g., for early detection of drug reactions and allergies. The project leader, Dr. Oswaldo Trelles, highlighted that one of the strengths of this study is its focus on medical practice. “The solutions we seek,” said Dr. Trelles “are targeted to a wide range of scientific applications, with personalized medicine certainly being one of them. Indeed, one of the objectives is to implement applications prototypes applied in real-use case scenarios and to evaluate their potential for detecting from genomic data of allergic patients the possible adverse reactions to treatment.”

The Mr. SymBioMath project represents an ideal opportunity for Integromics to reinforce its commitment to the development of software solutions for personalized medicine applied to the clinics. “This grant and collaboration with renowned computing experts will contribute to the democratization of genomics, in particular through the usage of mobile devices,” said Eduardo González Couto, CSO of Integromics.

Related Links:
Mr. SymBioMath Project
Integromics



Channels

Genomics/Proteomics

view channel
Image: Pulsed near infrared light (shown in red) is shone onto a tumor (shown in white) that is encased in blood vessels. The tumor is imaged by photoacoustic tomography via the ultrasound emission (shown in blue) from the gold nanotubes (Photo courtesy of Jing Claussen (iThera Medical, Germany)).

Gold Nanotubes Are Novel Agents for Cancer Diagnosis and Treatment

Cancer researchers have produced a highly defined class of gold nanotubes that are suitable for use in animals as in vivo imaging nanoprobes, photothermal conversion agents, and drug delivery vehicles.... Read more

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.